Efficacy and Safety of Azilsartan and Olmesartan in Patients with Essential Hypertension |
Molecule Updates
eMediNexus Coverage from: 
Efficacy and Safety of Azilsartan and Olmesartan in Patients with Essential Hypertension
eMediNexus,  05 March 2018
Coronavirus Live Count Map India

remove_red_eye 1278 Views
#Cardiology #Nephrology #Transplantation

4 Read Comments                

Several patients continue to have high blood pressure (BP) even after treatment with angiotensin II type 1 (AT1) receptor blockers (ARBs). The present study, published in the International Heart Journal, compared the efficacy and safety of azilsartan with olmesartan. Sixty-four hypertensive patients treated with ARBs other than azilsartan and olmesartan were recruited and randomized to changeover from their prior ARBs to either azilsartan or olmesartan. All patients were followed-up for 3 months. Systolic BP (SBP) was significantly reduced at 3 months in the azilsartan group, and diastolic BP (DBP) and pulse rate (PR) were significantly decreased in the olmesartan group after 3 months. No significant differences in ΔSBP, ΔDBP, or ΔPR (Δ = the value at 3 months minus the value at 0 months) could be noted between the groups. There seemed to be no difference in the depressor effects of azilsartan and olmesartan, and no serious changes in biochemical parameters were evident with azilsartan and olmesartan.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now